Particle.news

Download on the App Store

Hims & Hers Plans Canadian Launch of Generic Semaglutide After Zava Acquisition

Leveraging its Zava acquisition, Hims & Hers plans to broaden access to low-cost semaglutide pending Health Canada clearance.

Image
Image
Image
Image

Overview

  • The company closed its acquisition of European digital health platform Zava in July to extend its telehealth offerings into Canada and Europe.
  • Hims & Hers will introduce a Health Canada-approved generic semaglutide once Novo Nordisk’s Canadian patent officially expires in January.
  • It is collaborating with an approved partner to ensure full compliance with Canadian regulations before bringing the drug to market.
  • Following the announcement, Hims & Hers shares rose nearly 6%, reflecting investor confidence in its digital health expansion.
  • Rival Sandoz has already filed for Health Canada approval of a generic semaglutide, signaling an intensifying competitive landscape.